Case Reports
Journal Article
Review
Add like
Add dislike
Add to saved papers

Central toxic keratopathy: a case study and literature review.

BACKGROUND: Central toxic keratopathy (CTK) is a rare, non-inflammatory corneal opacity that can occur after corneal laser refractive surgery. It is characterized by the absence of inflammatory cells within the cornea or anterior chamber, central stromal necrosis, and corneal opacification, with an onset of 3 to 9 days after refractive surgery;

CASE STUDY: This case report reviews the clinical findings, differential diagnosis, possible etiologies, and management of CTK;

CONCLUSION: Though listed in the literature under numerous names, including diffuse lamellar keratitis (DLK) Stage IV, central lamellar keratitis (CLK), central flap necrosis (CFN), flap necrosis syndrome (FNS), and keratocyte-induced corneal microedema (KME), the conditions share characteristics with CTK, including clinical findings and treatment modalities. Treatment for CTK is controversial, though studies show best practices include close monitoring for possible corneal melt, avoiding topical corticosteroids, and possible enhancements for resultant hyperopia.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app